19 July 2012 
EMA/337034/2012 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Pradaxa 
dabigatran etexilate mesilate 
On  19  July  2012,  the  Committee  for  Medicinal  Products  for  Human  Use  (CHMP)  adopted  a  positive 
opinion  recommending  a  variation  to  the  terms  of  the  marketing  authorisation  for  the  medicinal 
product Pradaxa. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim 
International  GmbH.  They  may  request  a  re  examination  of  the  CHMP  opinion,  provided  that  they 
notify  the  European  Medicines  Agency  in  writing  of  their  intention  within  15  days  of  receipt  of  the 
opinion. 
The CHMP adopted a new contraindication as follows: 
"Concomitant  treatment  with  systemic  ketoconazole,  cyclosporine,  itraconazole,  tacrolimus  and 
dronedarone (see section 4.5)” 
Detailed  conditions  for  the  use  of  this  product  will  be  described  in  the  updated  summary  of  product 
characteristics  (SmPC),  which  will  be  published  in  the  revised  European  public  assessment  report 
(EPAR),  and  will  be  available  in  all  official  European  Union  languages  after  the  variation  to  the 
marketing authorisation has been granted by the European Commission. 
For information, the full contraindication for Pradaxa will be as follows2: 
  Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
  Patients with severe renal impairment (CrCL < 30 ml/min) 
  Active clinically significant bleeding 
  Organic lesion at risk of bleeding 
  Spontaneous or pharmacological impairment of haemostasis 
  Hepatic impairment or liver disease expected to have any impact on survival 
  Concomitant  treatment  with  systemic  ketoconazole,  cyclosporine,  itraconazole,  tacrolimus  and 
dronedarone (see section 4.5) 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
2 The text in bold represents the new or the amended contraindication. 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 8613 
E-mail info@ema.europa.eu  Website www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
                                                
